BETHESDA, Md., Dec. 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will be part of a panel discussion titled "Delivering On The Promise Of Antibody Therapies For Cancer" at the 2007 RBC Capital Markets Healthcare Conference in New York, on Wednesday, December 12, 2007 at 3:30pm Eastern Time (9:30pm Central European Time).
An audio webcast of Dr. Itin's remarks will be available live and accessible through Micromet's website at http://www.micromet-inc.com, as well as a replay and download of the presentation slides following the event.
About Micromet, Inc. (http://www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the
development of novel, proprietary antibodies for the treatment of cancer,
inflammation and autoimmune diseases. Three of its antibodies are in
clinical development. MT103 (MEDI-538), the first antibody developed using
the BiTE(R) technology platform to be clinically validated in Micromet's
product pipeline, is being evaluated in a phase 1 clinical trial for the
treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies
represent a new class of antibodies that activate a patient's own cytotoxic
T cells to eliminate cancer cells. Micromet is developing MT103 in
collaboration with MedImmune, a subsidiary of AstraZeneca plc. The second
clinical stage antibody is adecatumumab (MT201), a human monoclonal
antibody targeting EpCAM expressing tumors. Adecatumumab is being developed
by Micromet in collaboration with Merck Serono, a division of Merck KGaA in
Darmstadt, Germany, in a phase 1b clinical trial evaluating MT201 in
|SOURCE Micromet, Inc.|
Copyright©2007 PR Newswire.
All rights reserved